Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients

被引:48
|
作者
Levicar, N
Kos, J
Blejec, A
Golouh, R
Vrhovec, I
Frkovic-Grazio, S
Lah, TT
机构
[1] Natl Inst BIol, Dept Genet Toxicol & Canc Biol, Ljubljana 1000, Slovenia
[2] Jozef Stefan Inst, Dept Biochem & Mol Biol, Ljubljana 61111, Slovenia
[3] KRKA DD, Novo Mesto, Slovenia
[4] Inst Oncol, Dept Pathol, Ljubljana, Slovenia
[5] Inst Oncol, Dept Clin Biochem, Ljubljana, Slovenia
来源
CANCER DETECTION AND PREVENTION | 2002年 / 26卷 / 01期
关键词
cathepsin B; cathepsin L; stefin A; stefin B; urokinase (u-PA); PAI-1; breast cancer;
D O I
10.1016/S0361-090X(02)00015-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cysteine, serine and metalloproteinases and their respective inhibitors are involved in tumor cell invasion and may have prognostic value for the outcome of malignant disease. The aim of the study was to compare the expression of new potential biological tumor markers, the lysosomal cysteine proteinases and their endogenous inhibitors, with that of the serine proteinases and their inhibitors in breast cancinoma and to relate their levels to the clinicopathological factors of the disease. Enzyme-linked immunosorbent assays (ELISAs) were used to measure cysteine cathepsin B (CatB) and cathepsin L (CatL) and their inhibitors, stefin A (StA) and stefin B (StB), together with urokinase (u-PA) and plasminogen activator inhibitor-1 (PAI-1), in 150 cytosols of primary invasive breast carcinoma. A good correlation was found between the levels of the two cysteine proteinases but only a moderate one between those of the cysteine and serine proteinases. u-PA and PAI-1 levels correlated positively with histological grade and negatively with estrogen receptor (ER) status. PAI-1 correlated with most clinicopathological factors that indicate the progression of the disease, while cathepsins and stefins were independent of these factors. In the total group of patients, high u-PA and PAI-1 and low SIB levels correlated significantly with shorter disease-free survival (DFS), while CatB, CatL and StA did not. In lymph node negative patients, high CatB and CatL were also associated with shorter DFS, while u-PA remained the most significant of all these biological markers. In conclusion, this retrospective study showed u-PA to be of better prognostic relevance than the cysteine proteinases, though CatB and CatL were relevant for prognosis in lymph node negative breast cancer patients. (C) 2002 International Society for Preventive Oncology. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:42 / 49
页数:8
相关论文
共 38 条
  • [1] Cathepsin B and L and stefin A and B levels as serum tumor markers in squamous cell carcinoma of the head and neck
    Strojan, P
    Budinha, M
    Smid, L
    Svetic, B
    Vrhovec, I
    Skrk, J
    [J]. NEOPLASMA, 2001, 48 (01) : 66 - 71
  • [2] Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients
    Chen, Qingyong
    Fei, Jun
    Wu, Lijun
    Jiang, Zhongyong
    Wu, Yuquan
    Zheng, Yun
    Lu, Guohua
    [J]. ONCOLOGY LETTERS, 2011, 2 (04) : 693 - 699
  • [3] Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma
    Sinha, AA
    Quast, BJ
    Wilson, MJ
    Fernandes, ET
    Reddy, PK
    Ewing, SL
    Gleason, DF
    [J]. CANCER, 2002, 94 (12) : 3141 - 3149
  • [4] Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer
    Herszenyi, Laszlo
    Farinati, Fabio
    Cardin, Romilda
    Istvan, Gabor
    Molnar, Laszlo D.
    Hritz, Istvan
    De Paoli, Massimo
    Plebani, Mario
    Tulassay, Zsolt
    [J]. BMC CANCER, 2008, 8 (1)
  • [5] Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer
    László Herszényi
    Fabio Farinati
    Romilda Cardin
    Gábor István
    László D Molnár
    István Hritz
    Massimo De Paoli
    Mario Plebani
    Zsolt Tulassay
    [J]. BMC Cancer, 8
  • [6] STEFIN-A AND CATHEPSIN-B AND CATHEPSIN-L CIRCULATING SERUM LEVELS IN PATIENTS WITH MALIGNANT OR NONMALIGNANT LIVER-DISEASES - A PRELIMINARY-REPORT
    TUMMINELLO, FM
    PIZZOLANTI, G
    GEBBIA, N
    LETO, G
    [J]. MEDICAL SCIENCE RESEARCH, 1995, 23 (11): : 741 - 742
  • [7] Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma
    Häckel, CG
    Krueger, S
    Grote, HJ
    Oshiro, Y
    Hodges, S
    Johnston, DA
    Johnson, ME
    Roessner, A
    Ayala, AG
    Czerniak, B
    [J]. CANCER, 2000, 89 (05) : 995 - 1003
  • [8] Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis
    Farinati, F
    Herszenyi, L
    Plebani, M
    Carraro, P
    DePaoli, M
    Cardin, R
    Roveroni, G
    Rugge, M
    Nitti, D
    Grigioni, WF
    DErrico, A
    Naccarato, R
    [J]. CARCINOGENESIS, 1996, 17 (12) : 2581 - 2587
  • [9] Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: Comparison with cathepsin D, cathepsin L, and other clinical indicators
    Lah, TT
    Cercek, M
    Blejec, A
    Kos, J
    Gorodetsky, E
    Somers, R
    Daskal, I
    [J]. CLINICAL CANCER RESEARCH, 2000, 6 (02) : 578 - 584
  • [10] Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: Analysis of their prognostic significance in squamous cell carcinoma of the head and neck
    Strojan, P
    Budihna, M
    Smid, L
    Vrhovec, I
    Skrk, J
    [J]. ANTICANCER RESEARCH, 2000, 20 (5C) : 3975 - 3981